A randomized, dose-ranging study of Alferon (R) LDO [low dose interferon alfa-n3 (human leukocyte derived)] in asymptomatic HIV+ subjects

Trial Profile

A randomized, dose-ranging study of Alferon (R) LDO [low dose interferon alfa-n3 (human leukocyte derived)] in asymptomatic HIV+ subjects

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Interferon alpha-n3 (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top